1.Treatment results and prognostic factors of patients undergoing postoperative radiotherapy for laryngeal squamous cell carcinoma.
Ting JIN ; Wei-Han HU ; Li-Bing GUO ; Wen-Kuan CHEN ; Qiu-Li LI ; Hui LIN ; Xiu-Yu CAI ; Nan GE ; Rui SUN ; Si-Yi BU ; Xin ZHANG ; Meng-Yao QIU ; Wei ZHANG ; Su LUO ; Yi-Xin ZHOU
Chinese Journal of Cancer 2011;30(7):482-489
Postoperative radiotherapy (PRT) is widely advocated for patients with squamous cell carcinomas of the head and neck that are considered to be at high risk of recurrence after surgical resection. The aims of this study were to evaluate the treatment outcomes of PRT for patients with laryngeal carcinoma and to identify the value of several prognostic factors. We reviewed the records of 256 patients treated for laryngeal squamous cell carcinoma between January 1993 and December 2005. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Log-rank test was employed to identify significant prognostic factors for DFS and OS. The Cox proportional hazards model was applied to identify covariates significantly associated with the aforementioned endpoints. Our results showed the 3-, 5-, and 10-year DFS for all patients were 69.9%, 59.5%, and 34.9%, respectively. The 3-, 5-, and 10-year OS rates were 80.8%, 68.6%, and 38.8%, respectively. Significant prognostic factors for both DFS and OS on univariate analysis were grade, primary site, T stage, N stage, overall stage, lymph node metastasis, overall treatment times of radiation, the interval between surgery and radiotherapy, and radiotherapy equipment. Favorable prognostic factors for both DFS and OS on multivariate analysis were lower overall stage, no cervical lymph node metastasis, and using 60Co as radiotherapy equipment. In conclusion, our data suggest that lower overall stage, no cervical lymph node metastasis, and using 60Co as radiotherapy equipment are favorable prognostic factors for DFS and OS and that reducing the overall treatment times of radiation to 6 weeks or less and the interval between surgery and radiotherapy to less than 3 weeks are simple measures to remarkably improve treatment outcome.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Squamous Cell
;
pathology
;
radiotherapy
;
surgery
;
Cobalt Radioisotopes
;
therapeutic use
;
Combined Modality Therapy
;
Disease-Free Survival
;
Female
;
Follow-Up Studies
;
Humans
;
Laryngeal Neoplasms
;
pathology
;
radiotherapy
;
surgery
;
Laryngectomy
;
Lymphatic Metastasis
;
Male
;
Middle Aged
;
Neoplasm Grading
;
Neoplasm Staging
;
Postoperative Period
;
Proportional Hazards Models
;
Radioisotope Teletherapy
;
Retrospective Studies
;
Survival Rate
;
Young Adult
2.Combination of improved sex therapy and sildenafil for erectile dysfunction in Uigur men: retrospective analysis of 2505 cases.
Mu-la-jiang AI ; Er-ken AI ; Er-ban KU ; Mu-tu-la NI ; Er-mai-mai-ti NU ; Zhi-hua CAI ; A BU-DU-WAI-LI ; De-er KA ; Ke-bai-er AI ; Yi-er TA ; Si-hai-ti AI ; A DA-LI ; Qin XU
National Journal of Andrology 2010;16(3):261-263
OBJECTIVEThe sex therapy is not yet popularized at present. This study aimed to evaluate the effect of the combination of the improved sex therapy and oral sildenafil on erectile dysfunction (ED).
METHODSA total of 3130 Uigur cases of ED received in Xinjiang Bogda Hospital were divided into a control group (n=625) and a trial group (n=2505), the former treated with oral sildenafil alone, and the latter by the combination of the improved genital therapy and sildenafil, both for 3 months and followed up at 6 and 12 months after the treatment. The therapeutic effects were evaluated and compared using IIEF-5.
RESULTSThe IIEF-5 scores of the control group were 12.80 +/- 3.76 and 18.10 +/- 2.61 before and after the treatment, and 17.35 +/- 2.73 and 16.64 +/- 2.63 at 6 and 12 months, respectively, while those of the trial group were 12.73 +/- 3.52 and 19.06 +/- 4.07 before and af- ter the treatment, and 19.86 +/- 2.42 and 20.47 +/- 2.38 at 6 and 12 months, respectively, with statistically significant differences either between pre- and post-treatment (P < 0.05) or between the control and trial groups at 6 and 12 months (P < 0.05).
CONCLUSIONThe combination of the improved sex therapy and oral sildenafil is superior to sildenafil alone in the treatment of ED, and its efficacy is relatively stable at 12 months.
Adult ; Aged ; Asian Continental Ancestry Group ; Erectile Dysfunction ; drug therapy ; ethnology ; Humans ; Male ; Middle Aged ; Piperazines ; therapeutic use ; Purines ; therapeutic use ; Retrospective Studies ; Sildenafil Citrate ; Sulfones ; therapeutic use ; Treatment Outcome ; Young Adult